On August 11, 2022, Centrexion Therapeutics Corporation closed the transaction. The company has amended the terms of the transaction and received $5,390,000 in its third tranche bringing the total funds raised in the transaction to $29,140,000. The transaction included participation from 47 investors.

Maxim Group LLC will act as finder in the transaction and will receive fees of $2,622,600 in cash, approximately 475,954 shares and a warrant to purchase up to 1,748,400 shares.